UK Academy for Information Systems

Rgenta Therapeutics Announces Formation of Repeat Expansion Diseases Focused Scientific Advisory Board

Retrieved on: 
Wednesday, June 21, 2023

CAMBRIDGE, Mass., June 21, 2023 /PRNewswire/ -- Rgenta Therapeutics today announced the formation of a Repeat Expansion Diseases (REDs) Focused Scientific Advisory Board (REDs SAB).

Key Points: 
  • CAMBRIDGE, Mass., June 21, 2023 /PRNewswire/ -- Rgenta Therapeutics today announced the formation of a Repeat Expansion Diseases (REDs) Focused Scientific Advisory Board (REDs SAB).
  • REDs SAB is an esteemed group of preclinical and clinical experts who contribute to basic and translational research on the mechanisms and treatments for repeat expansion diseases.
  • "We are proud and honored to introduce our REDs focused SAB," said Dr Zhiping Weng, Rgenta SAB chair.
  • "Their knowledge and insights to the repeat expansion diseases will help advance the preclinical and clinical development of our small molecule programs."

Cambrian BioPharma Announces its Scientific Advisory Board led by Two Veteran R&D Executives

Retrieved on: 
Wednesday, September 14, 2022

NEW YORK, Sept. 14, 2022 /PRNewswire/ -- Cambrian BioPharma , a multi-asset longevity biotech, today announces its Scientific Advisory Board (SAB) and appointment of C. David Nicholson, PhD and Frank S. Walsh, PhD to lead.

Key Points: 
  • NEW YORK, Sept. 14, 2022 /PRNewswire/ -- Cambrian BioPharma , a multi-asset longevity biotech, today announces its Scientific Advisory Board (SAB) and appointment of C. David Nicholson, PhD and Frank S. Walsh, PhD to lead.
  • SAB reports are shared with individual pipeline companies for consideration in project strategy and planning and are also shared with the Cambrian BioPharma Board of Directors.
  • Moving forward Cambrian may add further SAB members or ad-hoc advisors as its pipeline grows and matures.
  • "Cambrian BioPharma is honored to have two highly experienced R&D executives to assist with our pursuit of expanding healthspan in the 21st century," said Brenton L. Saunders, Cambrian BioPharma Board of Directors.

Appointment of Kelly Beaver as CEO of Ipsos in UK & Ireland

Retrieved on: 
Wednesday, November 10, 2021

Paris, November 10, 2021 - Today Ipsos announces the appointment of Kelly Beaver as the new Chief Executive of the UK and Ireland businesses.

Key Points: 
  • Paris, November 10, 2021 - Today Ipsos announces the appointment of Kelly Beaver as the new Chief Executive of the UK and Ireland businesses.
  • Kelly will succeed Ben Page on 15 November when he moves to the role of Ipsos CEO*.
  • Kelly has been with Ipsos MORI for over a decade, during which time she has established and grown businesses and fostered high performing cultures.
  • Prior to joining Ipsos, Kelly held roles across various consultancies including PwC and KPMG.